- Home
- Product Candidates
- Overview
A Versatile Technology Platform
Designed with a purpose
Recce’s New Classes of Synthetic Anti-infectives are designed to address the urgent global health threat posed by antibiotic resistant superbugs
Recce Pharmaceuticals have developed two primary drug candidates: RECCE® 327 for bacterial infections and RECCE® 529 for viral infections. All RECCE® compounds are 100% water soluble at all pH levels in their liquid form. Recce Pharmaceuticals continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ bacterial and viral infections.
RECCE® 529
A synthetic anti-infective formulated for viral use
RECCE® 327
A fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms.
RECCE® 435
A broad spectrum synthetic polymer anti-microbial formulated for oral use
What Bacteria has R327
demonstrated capability against?
Clostridium difficile
Helicobacter pylori
Streptococcus pyogenes
Neisseria gonorrhoeae
Escherichia coli
Enterococcus faecium
Staphylococcus aureus
Klebsiella pneumoniae
Acinetobacter baumannii
Pseudomonas aeruginosa
Enterococcus species
E
S
K
A
P
E
Bacterial images courtesy of CDC.
R327 - Bacterial Infections
There is a historic lack of innovation in the antibiotic drug development field to address this growing need for effective antibiotics. R327 is one of the first new classes of anti-infectives in over 30 years with a universal mechanism of action that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.
ESKAPE Pathogens
Dubbed ESKAPE for their propensity of ‘escaping’ the biocidal action of antibiotics, the acronym stands for six different commonly found multi-drug resistant pathogens: Enterococcus faecium (E. faecium), Staphylococcus aureus (S. aureus), Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. baumannii), Pseudomonas aeruginosa (P. aeruginosa) and Enterobacter species.
An independent study was conducted by a contract research organisation to assess the in vitro efficacy of R327 against all ESKAPE pathogen bacterial strains. The results demonstrated R327 to be 99.9% effective against the full suite of ESKAPE pathogens, within minutes of exposure.